Ireland’s Minister for Health, Simon Harris, announced this week that Ireland is seeking to join Belgium, the Netherlands, Luxembourg, and Austria in their BeNeLuxA Initiative, a group that negotiates price deals on pharmaceuticals directly with manufacturers.
Ireland’s Minister for Health, Simon Harris, announced this week that Ireland is seeking to join Belgium, the Netherlands, Luxembourg, and Austria in their BeNeLuxA Initiative, a group that negotiates price deals on pharmaceuticals directly with manufacturers.
Harris wll now issue a letter of intent to the organization to formally signal Ireland’s interest in joining the collaboration and will travel to Belgium and the Netherlands in the coming weeks to begin discussions with an aim toward joining the bloc. In a statement, Harris said that that supply and price challenges are “…not unique to Ireland, and many countries are battling with the same issues. That is why, over the past [2] years, my department has been engaging with other European countries in an effort to identify solutions to medicines pricing, sustainability, and supply.”
The BeNeLuxA bloc was formed in 2015 with the mission to foster sustainable national healthcare systems in Europe, and to address the challenge of affordability of innovative therapies. The group participates in horizon scanning (seeking information about high-cost therapies that will be become available in the near future), health technology assessments (HTAs), information sharing and policy exchange, and—critically—price negotiations with industry.
According to a discussion paper published the European Public Health Alliance (EPHA) in 2017, health ministers from the Netherlands and Belgium first saw the need for such a negotiating bloc after drug maker Gilead introduced the high-cost sofosbuvir (Sovaldi) in the European marketplace. Realizing the potential for expensive drugs to strain health systems, the founding member states felt that they needed to increase their bargaining power with drug makers.
According to EPHA, drug makers “are used to negotiating bilaterally with national governments. This puts them in a favorable position, having a panoramic overview of each of the 28 EU member states’ pharmaceutical policies, purchasing power, and willingness to pay.” At the same time, national governments lack insight into neighboring countries’ policies, creating an asymmetry of information on drug pricing.
Thus far, BeNeLuxA has not had major successes to report; in May 2017, the bloc announced that it had not been able to reach a deal with drug maker Vertex on its lumacaftor/ivacaftor drug combination for the treatment of cystic fibrosis, which, according to an HTA undertaken by BeNeLuxA, was worth 82% less than Vertex’s asking price. The governments represented by BeNeLuxA declined to supply the drug in their healthcare systems, so patients will not have access to the therapy.
Furthermore, the paper notes that there exists a concern among policy makers that drug companies may attempt to discourage efforts like BeNeLuxA by refusing to negotiate so as not to set a new precedent. EPHA suggests that, as a potential solution, “Governments might wish to respond by making the BeNeLuxA route the only available option for reimbursement of a company’s products or for some clusters of products.”
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.